Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 5/20 | 0.60 |
| ▸ | JAK3 | P52333 | 4/20 | 0.55 |
| ▸ | TTBK1 | Q5TCY1 | 6/20 | 0.54 |
| ▸ | TTBK2 | Q6IQ55 | 6/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1086048 | 0.81 | TTBK1 (0.60) | TRPA1JAK3TTBK1TTBK2BRD4 | |
| SCHEMBL2540294 | 0.81 | TRPA1 (0.53) | TRPA1JAK3TTBK1TTBK2MKNK1 | |
| SCHEMBL12561811 | 0.78 | TRPA1 (0.53) | TRPA1JAK3TTBK1TTBK2JAK2 | |
| SCHEMBL21262326 | 0.76 | TRPA1 (0.51) | TRPA1JAK3TTBK1TTBK2BRD4 | |
| SCHEMBL18680737 | 0.76 | TRPA1 (0.51) | TRPA1JAK3TTBK1TTBK2MKNK1 | |
| SCHEMBL16912583 | 0.75 | TRPA1 (0.50) | TRPA1JAK3TTBK1TTBK2TNNI3K | |
| SCHEMBL22569504 | 0.75 | TRPA1 (0.50) | TRPA1JAK3TTBK1TTBK2BRD4 | |
| SCHEMBL24671871 | 0.74 | ENPP1 (0.42) | — | |
| SCHEMBL22508755 | 0.74 | TTBK1 (0.59) | TTBK1TTBK2MKNK1MKNK2 | |
| SCHEMBL7958023 | 0.74 | HRH4 (0.45) | TRPA1TTBK1TTBK2MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739671-A1 | NEW COMPOUNDS | Aston University (GB) | 2026-05-13 | — | — | EP | disclosed |
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SHIVALILA CHIKDU SHAKTI (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD (SG) | 2025-08-21 | — | — | US | disclosed |
| CN-120118141-A | Nucleoside analogues and uses thereof | 广州市恒诺康医药科技有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| US-20250135036-A1 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2025-05-01 | — | — | US | disclosed |
| EP-4522744-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2025-03-19 | — | — | EP | disclosed |
| EP-4507700-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | Wave Life Sciences Ltd. (SG) | 2025-02-19 | — | — | EP | disclosed |
| CN-119452084-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20250041319-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2025-02-06 | — | — | US | disclosed |
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7259154-B2 | Anticancer agents; asthma; rhintis; vision disorders; skin disorders; antiarthritic agents; antiinflammatory agents; antiallergens | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20040142947-A1 | Pyrrolopyrimidines | AVENTIS PHARMACEUTICALS, INC. | 2004-07-22 | — | — | US | disclosed |
| EP-1404676-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003000695-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, PRKACA, RAF1 | TRPA1 574/4885JAK3 127/4885TTBK1 325/4885 |
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | ADAR, NSUN2, RNGTT | TRPA1 3949/4885JAK3 1512/4885TTBK1 4154/4885 |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | ADAR, RNGTT, NSUN2 | TRPA1 4881/4885JAK3 2629/4885TTBK1 4097/4885 |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | TRPA1 3284/4885JAK3 61/4885TTBK1 1366/4885 |
| US-20250135036-A1 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | MECP2, ADAR, NSUN2 | TRPA1 4524/4885JAK3 2321/4885TTBK1 2901/4885 |
| US-20250041319-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, SMPD1 | TRPA1 4787/4885JAK3 4175/4885TTBK1 2853/4885 |
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | MCOLN1, TRPM2, PKD2 | TRPA1 30/4885JAK3 4405/4885TTBK1 434/4885 |
| US-20040142947-A1 | Pyrrolopyrimidines | DPYD, TYMP, PNPO | TRPA1 4633/4885JAK3 2850/4885TTBK1 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.